Thalidomide therapy for aggressive histiocytic lesions in the pediatric population

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 6, 2012, Pages 480-483

  Bailey, Kelly M ^a   Castle, Valerie P ^a   Hummel, Jennifer M ^b,c   Piert, Morand ^d   Moyer, Judith ^a   McAllister Lucas, Linda M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d University Hospital   (United States)

Author keywords

histiocytic sarcoma; juvenile xanthogranuloma; thalidomide

Indexed keywords

ALEMTUZUMAB; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISONE; THALIDOMIDE; VINBLASTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HISTIOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE XANTHOGRANULOMA; LEG PAIN; LEUKEMIA REMISSION; LONG TERM CARE; LYMPH NODE DISSECTION; MIGRAINE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SYNCOPE;

ADOLESCENT; CHILD; FEMALE; HISTIOCYTIC SARCOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICHIGAN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; THALIDOMIDE; XANTHOGRANULOMA, JUVENILE;

EID: 84864332372     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182580d6e     Document Type: Article

References (19)

1. Somers GF. Pharmacological properties of thalidomide (alphaphthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol Chemother. 1960;15:111-116.
2. Baidas S, Tfayli A, Bhargava P. Thalidomide: An old drug with new clinical applications. Cancer Invest. 2002;20:835-848.
3. Bessmertny O, Pham T. Thalidomide use in pediatric patients. Ann Pharmacother. 2002;36:521-525.
4. Ng-Chen-Hin B, O'Hanlon-Brown C, Alifrangis C, et al. Langerhans cell histiocytosis: Old disease and new treatment. QJM. 2010;104:89-96.
5. McClain K, Kozinetz CA. Phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48:44-49.
6. Ladizinski B, Shannon EJ, Sanchez MR, et al. Thalidomide and analogues: Potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. J Drugs Dermatol.2010;9:814-826.
7. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91: 4082-4085.
8. Hornick JL, Jaffe ES, Fletcher C. Extranodal histiocytic sarcoma: Clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004;28:1133-1144.
9. Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: An immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1-29.
10. Vos JA, Abbondanzo SL, Barekman CL, et al. Histiocytic sarcoma: A study of five cases including the histiocyte marker CD163. Mod Pathol. 2005;18:693-704.
11. Freyer DR, Kennedy R, Bostrom BC, et al. Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications. J Pediatr. 1996;129:227-237.
12. Sangüeza OP, Salmon JK, White CR, et al. Juvenile xanthogranuloma: A clinical, histopathologic and immunohistochemical study. J Cutan Pathol. 1995;22:327-335.
13. Dalle JH, Leblond P, Decouvelaere A, et al. Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL Leukemia. Leukemia. 2003;17:2056-2057.
14. Abidi MH, Tove I, Ibrahim RB, et al. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol. 2007;82:932-933.
15. Gergis U, Dax H, Ritchie E, et al. Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: A case report and review of the literature. J Clin Oncol. 2011;29:251-253.
16. Perez-Becker R, Szczepanowski M, Leuschner I, et al. An aggressive systemic juvenile xanthogranuloma clonally related to a preceding T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56:859-862.
17. Dehner LP. Juvenile xanthogranulomas in the first two decades of life: A clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol. 2003;27:579-593.
18. Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer. 2008;51:130-133.
19. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.